2017 HIV Virtual Patient: Clinical Management of Key Treatment Decisions


HIV Virtual Patient 17 v3

About the Program

Program Overview

Antiretroviral therapy (ART) has evolved considerably over the past three decades. With many antiretroviral (ARV) drugs, combinations and classes available, health care providers have multiple choices regarding ARV therapy.  In recent years, significant progress has been made in the treatment of HIV, but many clinicians who manage patients infected with HIV are not aware of the full range of complex and emerging treatment options available or how to apply them to various patient scenarios. Due to the rapidly changing landscape in HIV management, this situation can significantly affect the treatment of patients with HIV infection and the quality of the care they receive, potentially affecting patient outcomes, increasing morbidity, mortality, and treatment costs.

The HIV Virtual Patient program is an interactive, case-based program featuring real-world case scenarios discussed by HIV thought leaders.  Participants will be asked to assess and treat a variety of HIV-positive and HIV-negative patient types with the direction and consultation of HIV thought leaders. This program provides important information that can be directly applied to clinical practice, thereby increasing the delivery of optimal care to patients with HIV infection in the United States.

Back to Top

Target Audience

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.

Back to Top

Learning Objectives

After completing this activity, participants should be better able to:

  • Apply in clinical practice approaches for preventing HIV infection and getting newly diagnosed patients linked to care
  • Individualize ARV therapy for the treatment-naïve and treatment-experienced patients to provide optimal ARV therapy
  • Manage HIV patients with HIV/HCV co-infection
  • Manage aging patients with HIV infection to maintain viral suppression while addressing issues associated with cardiovascular, renal, and bone disease

Release Date: May 9, 2017

Expiration Date: May 9, 2018

Estimated time to complete each Virtual Patient Case:  30-60 minutes

Media: Internet

Back to Top


Richard A. Elion, MD
Associate Professor of Clinical Medicine
George Washington University Medical Center
Washington, DC
Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research
Perelman School of Medicine
at the University of Pennsylvania
Philadelphia, Pennsylvania
Wilbert Jordan, MD
Medical Director
Charles Drew Medical Center
Los Angeles, California
Paul Sax, MD, MD
Clinical Director
Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Renslow Sherer, MD
Professor of Medicine,
Section of Infectious Diseases and Global Health
University of Chicago
Chicago, Illinois
Kathleen E. Squires, MD
W Paul and Ida H Havens Professor of Infectious Diseases
Director, Division of Infectious Diseases
Sidney Kimmel Medical College of Thomas Jefferson University
Medical Director, Infectious Diseases and Population Management
Jefferson Health System
Philadelphia, Pennsylvania
Pablo Tebas, MD
Professor of Medicine
Hospital of the University of Pennsylvania
Director, Adult AIDS Clinical Trials Unit (ACTU)
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
Back to Top

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

For Cases 1,2,3,4,5,6

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

For Cases 7,8,9,10

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 


Back to Top

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Richard Elion, MD

  • Consulting Fees: Gilead, ViiV
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest: Gilead, Merck, Janssen
Ian Frank, MD
  • Consulting Fees: Gilead
  • Contracted Research: ViiV/GSK


Wilbert Jordan, MD

  • Consulting Fees: Gilead
Paul Sax, MD
  • Consulting Fees: AbbVie, BMS, GSK/ViiV, Gilead, Janssen, Merck
  • Contracted Research: Gilead, BMS, GSK/ViiV

Renslow Sherer, MD

  • Consulting Fees: Gilead

Kathleen Squires, MD

  • Consulting Fees: BMS, Gilead, Janssen, Merck, ViiV
  • Contracted Research: Gilead

Pablo Tebas, MD

  • Consulting Fees: Merck
  • Other - Adjudication committee: GSK

David Wohl, MD

  • Consulting Fees: Gilead, ViiV, BMS
  • Contracted Research: Gilead, ViiV

The PIM planners and managers, Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, RN, BSN and Jan Shultz, RN, MSN, CHCP have nothing to disclose.

Back to Top

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this activity. During the period, May 9, 2017 through May 9, 2018, participants must read the learning objectives and faculty disclosures and study the educational activity.

PIM supports Green CME by offering your Request for Credit online. If you wish to received acknowledgment of completing this activity, please complete the post-test and evaluation on www.cmeuniversity.com. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 12282. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

Back to Top

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.




This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs



Back to Top



Prepare to print

Share this page:

Get link code to this page                     

Back to Top